Phase 1, Two-arm, Open-label Study of Once Daily, Oral BMN 673 in Patients With Advanced Hematological Malignancies.
Phase of Trial: Phase I
Latest Information Update: 23 Dec 2015
At a glance
- Drugs Talazoparib (Primary)
- Indications Haematological malignancies
- Focus Adverse reactions
- Sponsors BioMarin Pharmaceutical
- 21 May 2014 Status changed from active, no longer recruiting to discontinued as reported by ClinicalTrials.gov record.
- 15 Mar 2013 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
- 15 Mar 2012 Additional lead trial investigators identified as reported by ClinicalTrials.gov.